Definium Therapeutics Stock Market Outlook
| DFTX Stock | 16.25 0.78 4.58% |
Slightly above 55% of Definium Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Definium Therapeutics suggests that many traders are impartial. Definium Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Definium Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 45
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Definium Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Definium Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Definium Therapeutics is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Definium Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Definium Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Definium Therapeutics Advice
The Definium recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Definium Therapeutics. Macroaxis does not own or have any residual interests in Definium Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Definium Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Definium Therapeutics has a Mean Deviation of 3.23, Semi Deviation of 3.64, Standard Deviation of 4.16, Variance of 17.29, Downside Variance of 14.34 and Semi Variance of 13.22Our trade advice tool can cross-verify current analyst consensus on Definium Therapeutics and to analyze the company potential to grow in the current economic cycle. Please use Definium Therapeutics total debt and net asset to make buy, hold, or sell decision on Definium Therapeutics. Given that Definium Therapeutics has a number of employees of 74, we urge you to verify Definium Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Definium Therapeutics Trading Alerts and Improvement Suggestions
| Definium Therapeutics appears to be risky and price may revert if volatility continues | |
| Definium Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Definium Therapeutics was previously known as Mind Medicine and was traded on NASDAQ Exchange under the symbol MNMD. | |
| Net Loss for the year was (108.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Definium Therapeutics generates negative cash flow from operations | |
| Definium Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from simplywall.st: Is Adsetts Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics |
Definium Therapeutics Returns Distribution Density
The distribution of Definium Therapeutics' historical returns is an attempt to chart the uncertainty of Definium Therapeutics' future price movements. The chart of the probability distribution of Definium Therapeutics daily returns describes the distribution of returns around its average expected value. We use Definium Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Definium Therapeutics returns is essential to provide solid investment analysis for Definium Therapeutics.
| Mean Return | 0.29 | Value At Risk | -4.86 | Potential Upside | 7.13 | Standard Deviation | 4.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Definium Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Definium Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Definium Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Definium Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Definium stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.27 | |
β | Beta against Dow Jones | 0.16 | |
σ | Overall volatility | 3.89 | |
Ir | Information ratio | 0.06 |
Definium Therapeutics Volatility Alert
Definium Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Definium Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Definium Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Definium Therapeutics Fundamentals Vs Peers
Comparing Definium Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Definium Therapeutics' direct or indirect competition across all of the common fundamentals between Definium Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Definium Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Definium Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Definium Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Definium Therapeutics to competition |
| Fundamentals | Definium Therapeutics | Peer Average |
| EBITDA | (105.87 M) | 3.9 B |
| Net Income | (108.68 M) | 570.98 M |
| Total Debt | 21.85 M | 5.32 B |
| Cash Flow From Operations | (79.13 M) | 971.22 M |
| Number Of Employees | 74 | 18.84 K |
| Total Asset | 302.15 M | 29.47 B |
| Retained Earnings | (398.88 M) | 9.33 B |
| Working Capital | 242.77 M | 1.48 B |
| Net Asset | 302.15 M |
Definium Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Definium . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 110331.0 | |||
| Daily Balance Of Power | (0.69) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 16.74 | |||
| Day Typical Price | 16.57 | |||
| Price Action Indicator | (0.88) | |||
| Period Momentum Indicator | (0.78) |
Definium Therapeutics Analyst Ratings
Definium Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Definium Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Definium Therapeutics' financials, market performance, and future outlook by experienced professionals. Definium Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Definium Therapeutics Buy or Sell Advice
When is the right time to buy or sell Definium Therapeutics? Buying financial instruments such as Definium Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2025 | 2026 (projected) | Working Capital | 171.4K | 147.7K | Market Cap | 129.0M | 89.2M |
Use Investing Ideas to Build Portfolios
In addition to having Definium Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 111 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.